Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep

Vaccine

Volumn 26, Issue 41, 2008, Pages 5255-5262

  Lorenzo, Gema ^a   Martín Folgar, Raquel ^a   Rodríguez, Fernando ^b   Brun, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b CENTRE DE RECERCA EN SANITAT ANIMAL CRESA   (Spain)

Author keywords

DNA vaccination; Prime boost; RVFV

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; NUCLEOPROTEIN N; PLASMID DNA; PLASMID VECTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN G1; VIRUS GLYCOPROTEIN G2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENCY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MEMORY CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PLASMID; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; SHEEP; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; GLYCOPROTEINS; NUCLEOCAPSID PROTEINS; PLASMIDS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; SHEEP DISEASES; VACCINES, ATTENUATED; VACCINES, DNA; VERO CELLS; VIRAL VACCINES;

EID: 50849118120     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.042     Document Type: Article

References (31)

1. Gerdes G.H. Rift Valley fever. Rev Sci Tech 23 August(2) (2004) 613-623
2. Flick R., and Bouloy M. Rift Valley fever virus. Curr Mol Med 5 December(8) (2005) 827-834
3. Ahmad K. More deaths from Rift Valley fever in Saudi Arabia and Yemen. Lancet 356 October(9239) (2000) 1422
4. Anyamba A., Chretien J.P., Formenty P.B., Small J., Tucker C.J., Malone J.L., et al. Rift Valley fever potential, Arabian Peninsula. Emerg Infect Dis 12 March(3) (2006) 518-520
5. Lopez-Velez R., and Molina Moreno R. Climate change in Spain and risk of infectious and parasitic diseases transmitted by arthropods and rodents. Rev Esp Salud Publica 79 March-April(2) (2005) 177-190
6. Randall R., Binn L.N., and Harrison V.R. Immunization against Rift Valley fever virus studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J Immunol 93 August (1964) 293-299
7. Caplen H., Peters C.J., and Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 October(Pt 10) (1985) 2271-2277
8. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 53 October(4) (1995) 405-411
9. Meadors III G.F., Gibbs P.H., and Peters C.J. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine 4 September(3) (1986) 179-184
10. Smithburn K. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30 February(1) (1949) 1-16
11. Zeller H., and Bouloy M. Infections by viruses of the families Bunyaviridae and Filoviridae. Rev Sci Tech 19 April(1) (2000) 79-91
12. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 78 June(6) (2006) 787-791
13. Rodriguez F., and Whitton J.L. Enhancing DNA immunization. Virology 268 March(2) (2000) 233-238
14. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., and Schmaljohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine (2005) September 17
15. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., and Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24 November(49-50) (2006) 7181-7189
16. Sall A.A., Zanotto P.M., Sene O.K., Zeller H.G., Digoutte J.P., Thiongane Y., et al. Genetic reassortment of Rift Valley fever virus in nature. J Virol 73 October(10) (1999) 8196-8200
17. Morrill J.C., and Peters C.J. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21 June(21-22) (2003) 2994-3002
18. Hunter P., Erasmus B.J., and Vorster J.H. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 69 March(1) (2002) 95-98
19. Schmaljohn C.S., Parker M.D., Ennis W.H., Dalrymple J.M., Collett M.S., Suzich J.A., et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170 May(1) (1989) 184-192
20. Överby A., Popov V., Neve E., and Pettersson R.F. Generation and analysis of infectious virus-like particles of Uukuniemi virus (Bunyaviridae): a useful system for studying bunyaviral packaging and budding. J Virol 80 (2006) 10428-10435
21. Lorenzo G., Martín R., García A., Borrego B., Rodríguez F., and Brun A. Antigenic and immunogenic properties of recombinant Rift Valley fever virus structural proteins. 7th international congress from the European society of veterinary virology. Lisbon, Portugal (2006)
22. Suzich J.A., and Collett M.S. Rift Valley fever virus M segment: cell-free transcription and translation of virus-complementary RNA. Virology 164 June(2) (1988) 478-486
23. Kakach L.T., Wasmoen T.L., and Collett M.S. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study phlebovirus gene expression. J Virol 62 March(3) (1988) 826-833
24. Kakach L.T., Suzich J.A., and Collett M.S. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology 170 June(2) (1989) 505-510
25. Suzich J.A., Kakach L.T., and Collett M.S. Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment. J Virol 64 April(4) (1990) 1549-1555
26. Gerrard S.R., and Nichol S.T. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357 January(2) (2007) 124-133
27. Mebatsion T., Koolen M., de Vaan L., de Haas N., Braber M., Römer-Oberdörfer A., et al. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol 76 20 (2002) 10138-10146
28. Le May N., Gauliard N., Billecocq A., and Bouloy M. The N terminus of Rift Valley fever virus nucleoprotein is essential for dimerization. J Virol 79 September(18) (2005) 11974-11980
29. Quan F., Huang C., Compans R., and Kang S. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81 7 (2007) 3514-3524
30. Niborski V., Brennan Y.L., Lane F., Torché M., Remond A., et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 24 49-50 (2006) 7204-7213
31. Keegan K., and Collett M.S. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 58 May(2) (1986) 263-270